CompoAtlas

超燃紅橙錠

超燃紅橙錠 : Product registered in Taiwan. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.

TFDA, Taiwan tablets, capsules and medical nutrition registers, retrieved 27 October 2026.

Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0

Open Government Data License, version 1.0

The foreign register category does not determine the regulatory category of the product in France.

French and European references for recognised ingredients

No point flagged by the rules applied to recognised ingredients.

Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.

Published composition

Published ingredientPublished text and quantityIdentified nutrient or substance
ISOMALTISOMALTNot identified
MALTODEXTRINMALTODEXTRINMaltodextrine
RED ORANGE EXTRACTRED ORANGE EXTRACTNot identified
L-CARNITINEL-CARNITINEL-carnitine
AFRICA MANGO EXTRACTAFRICA MANGO EXTRACTNot identified
CHITOSANCHITOSANChitosan
GARCINIA EXTRACTGARCINIA EXTRACTNot identified
CORN STARCHCORN STARCHNot identified
PROPYLENE GLYCOLPROPYLENE GLYCOLNot identified
KETONESKETONESCétones
AROMATIC ALCOHOLSAROMATIC ALCOHOLSNot identified
ESTERSESTERSNot identified
DEXTRINDEXTRINNot identified
MAGNESIUM STEARATEMAGNESIUM STEARATENot identified
DEXTROSE MONOHYDRATEDEXTROSE MONOHYDRATENot identified
AROMATIC ALDEHYDESAROMATIC ALDEHYDESNot identified
SILICON DIOXIDESILICON DIOXIDENot identified
BLACK VINEGAR POWDERBLACK VINEGAR POWDERNot identified
CONCENTRATED BLACK VINEGARCONCENTRATED BLACK VINEGARNot identified
PURPLE TEA EXTRACTPURPLE TEA EXTRACTNot identified
CITRIC ACIDCITRIC ACIDAcide citrique
POTATO STARCHPOTATO STARCHNot identified
SHEKWASHA JUICESHEKWASHA JUICENot identified
SUCRALOSESUCRALOSENot identified

The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.

Product record

Registration number
1110708618
Chinese name
超燃紅橙錠
English name
ZENSO KURO OIRU
Type
Imported tablets and capsules
Published status
Status not provided in this export; the validity date is shown separately
Licence holder
唯樂生物科技股份有限公司
Registration date
2022-06-01
Published validity end
2027-06-01

Original register data

View published fields and their variants
Product name
超燃紅橙錠
Active ingredients
ISOMALT;;MALTODEXTRIN;;RED ORANGE EXTRACT;;L-CARNITINE;;AFRICA MANGO EXTRACT;;MALTODEXTRIN;;CHITOSAN;;GARCINIA EXTRACT;;CORN STARCH;;PROPYLENE GLYCOL;;KETONES;;AROMATIC ALCOHOLS;;ESTERS;;DEXTRIN;;MAGNESIUM STEARATE;;DEXTROSE MONOHYDRATE;;AROMATIC ALCOHOLS;;AROMATIC ALDEHYDES;;ESTERS;;KETONES;;SILICON DIOXIDE;;BLACK VINEGAR POWDER;;CONCENTRATED BLACK VINEGAR;;PURPLE TEA EXTRACT;;MALTODEXTRIN;;CITRIC ACID;;DEXTRIN;;POTATO STARCH;;SHEKWASHA JUICE;;SUCRALOSE;;
Valid until
1160601
Registration number
1110708618
Licence holder
唯樂生物科技股份有限公司
Registration date
1110601
Published reference
DHC0B107086180
Published English name
ZENSO KURO OIRU

Official source

View the official register, number 1110708618

Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0

Open Government Data License, version 1.0

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • L-CARNITINE
    Read the warning, when it applies and the studies cited

    L-CARNITINE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (CPS 2008).

    Sources cited by Health Canada (1)
    • CPS 2008: Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a seizure disorder (CPS 2008).

    Sources cited by Health Canada (1)
    • CPS 2008: Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Health Canada monograph dated 25 July 2025

  • CHITOSAN
    Read the warning, when it applies and the studies cited

    CHITOSAN

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Pittler et al. 1999).

    Sources cited by Health Canada (1)
    • Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomized, double-blind trial of chitosan for body weight reduction. European Journal of Clinical Nutrition 1999;53(5):379-381. PubMed Randomised trial

    Condition of application: All products (except for weight management).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Condition of application: Weight management.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.

    Contraindications

    Condition of application: All products.

    Do not use if you have an allergy to seafood.

    Condition of application: Weight management.

    Do not use if you are pregnant (HC 2010).

    Sources cited by Health Canada (2)
    • HC 2010: Health Canada: Prenatal Nutrition Guidelines for health Professionals: Gestational weight gain [Accessed 2024 April 7]. Available from: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-eng.pdf
    • SC 2010 : Santé Canada : Lignes directrices sur la nutrition pendant la grossesse à l'intention des professionnels de la santé : Gain de poids pendant la grossesse. [Consulté le 7 avril 2024]. Disponible à : https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-fra.pdf

    Known adverse reactions

    When using this product you may experience gastrointestinal discomfort/disturbances (Moraru et al. 2018; Mhurchu et al. 2004; Pittler et al. 1999).

    Sources cited by Health Canada (3)
    • Mhurchu CN, Poppitt SD, McGill AT, Leahy FE, Bennett DA, Lin RB, Ormrod D, Ward L,Strik C, Rodgers A. (on behalf of the Effect of Chitosan on Health and Obesity (ECHO) Collaboration). The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. International Journal of Obesity 2004;28:1149-1156. PubMed Randomised trial
    • Moraru C, Mincea MM, Frandes M, Timar B, Ostafe V. A Meta-Analysis on Randomised Controlled Clinical Trials Evaluating the Effect of the Dietary Supplement Chitosan on Weight Loss, Lipid Parameters and Blood Pressure. Medicina (Kaunas) 2018; 54(6):109. PubMed Meta-analysis
    • Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomized, double-blind trial of chitosan for body weight reduction. European Journal of Clinical Nutrition 1999;53(5):379-381. PubMed Randomised trial

    Health Canada monograph dated 29 November 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “超燃紅橙錠”, https://compoatlas.com/en/supplements/taiwan/1110708618-zenso-kuro-oiru, updated 27 October 2026.

Enter to analyse, Shift+Enter for a new line